Overview
Exploring the Therapeutic Potential of Emerging Therapies in Pulmonary Fibrosis
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
This activity is intended for pulmonologists and advanced practice providers in pulmonology settings.
Fibrosing interstitial lung diseases (ILD) encompass a range of disorders such as idiopathic pulmonary fibrosis and systemic autoimmune rheumatic disease-associated ILD. This heterogeneous group of disorders includes a subset of patients who experience progressive pulmonary fibrosis (PPF) with declines in lung function over time. This progression is often accompanied by worsening symptoms, such as dyspnea, cough, and fatigue, and can lead to high rates of hospitalization and death.
Effective management of PPF necessitates a multidisciplinary approach, demanding proficiency in the most up-to-date diagnostic techniques, therapeutic interventions, and supportive care strategies. Treatment guidelines recommend antifibrotic agents and supportive care strategies such as oxygen therapy and pulmonary rehabilitation. Agents with novel antifibrotic and anti-inflammatory mechanisms of action are now available with additional approaches on the horizon; yet evidence indicates that use of antifibrotic therapies is suboptimal with many patients receiving treatment late in disease progression.
Dive into this unique educational experience with CrossMED™! This engaging activity combines clue-based crosswords with word games to test your knowledge. Then, immerse yourself in expert videos, resources, and supporting data to increase your proficiency with the integration of novel therapies for PPF. Support better outcomes for your patients through this fun and engaging learning opportunity today!
Upon completion of this activity, learners will be able to:
- Discuss unmet needs associated with standard of care for treating pulmonary fibrosis
- Evaluate current and emerging antifibrotic therapies for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) in terms of efficacy, adverse events (AEs), and patient suitability
- Identify opportunities to integrate emerging pharmacologic interventions into patient-centered care plans to alleviate the clinical burden associated with fibrosing ILDs
This educational activity is presented in collaboration with Rush University Medical Center and the Academy for Continued Healthcare Learning (ACHL).
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Toby Maher, MD, MSc, PhD
Professor of Clinical Medicine
Director of ILD, PCCSM
Keck Medicine of USC
Los Angeles, CA
Professor of Clinical Medicine
Director of ILD, PCCSM
Keck Medicine of USC
Los Angeles, CA
Samuel Fox, MD
Assistant Professor of Medicine, Attending Physician
Division of Pulmonary/Critical Care Medicine, Department of internal Medicine
Rush University Medicine
Chicago, IL
It is the policy of the Interprofessional Continuing Education office at Rush to ensure that its CE activities are independent, free of commercial bias. Therefore, we manage all financial relationships associated with accredited continuing education activities. Rush asks everyone who has the ability to control or influence the content of an educational activity to disclose information about all of their financial relationships with ineligible companies within the prior 24 months. An ineligible company is an entity whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. There is no minimum threshold; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose regardless of their view of the relevance of relationships to education. Mechanisms are in place to identify and mitigate any potential conflicts of interest prior to the planning, implementation, or evaluation of the continuing education activity. If a financial relationship is identified for the person in control of content, conflict mitigation strategies will be used to mitigate the financial relationship before they assume their role.
Individuals in control of content for this activity have the following relevant financial relationships with ineligible companies to disclose and all financial relationships have been mitigated.
The following financial relationships have been provided:
Toby Maher, MD, MSc
Consulting Agreements: AbbVie, AstraZeneca, Bristol Meyers Squibb, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Pfizer, PureTech, UCB, United Therapeutics
Speakers' Bureau: United Therapeutics
Samuel Fox, MD
No financial relationships to disclose
Allison Lall, RN
No financial relationships to disclose
Rush University Medical Center and the Office of Interprofessional Continuing Education staff members, ACHL staff members, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships with ineligible companies.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: admilparant, TTI-101, deupirfenidone, and inhaled treprostinil
This activity will take approximately 75 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66.67% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact McKenna Reinhard at mreinhard@achlcme.org or (877) 444-8435 ext. 121.
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Rush University Medical Center designates this Enduring Material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
Rush University Medical Center designates this Enduring Material for a maximum of 1.25 nursing contact hour(s).
